pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO
ALX ONCOLOGY HOLDINGS
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS is a pharma organization headquartered in San Antonio, USA. It trades on NYSE under ticker ALXO. Primary therapeutic focus areas include Breast Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), A
4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US HQ
2015 Founded
2 Employees
Public company Type
ALXO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
- Founded
- 2015
- Employees
- 2
- Programs
- 13
- Drugs
- 16
- Patents
- 0
Zanidatamab
Phase 2 · small molecule · HER2-expressing Cancers
Zanidatamab for HER2-expressing Cancers is a Phase 2 program (small_molecule) at ALX ONCOLOGY HOLDINGS INC with 1 ClinicalTrials.gov record(s).
Internal code ZWI-ZW25-204
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ALX ONCOLOGY HOLDINGS INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- HER2-expressing Cancers
- Status
- completed
- Trials
- 1